Z6·尊龙凯时

Research and Development

Strong, Innovation-driven R&D Capabilities

R&D Field

Cancer Types Covered by the R&D Pipeline

Lung
Cancer
Breast
Cancer
Gastric
Cancer
Gynecological
Cancer
Hematologic
Malignancies

Rich and Balanced Pipeline

1 product – Gumarontinib, an oral highly selective mesenchymal-epithelial transition (MET) inhibitor and a Category 1 innovative new chemical drug has been conditionally approved by NMPA that Haihe owns its global intellectual property rights.
10+ Oncology+Non-oncology compounds in core pipeline, including those in late clinical stage and pre-clinical stage
Multiple potential best-in-class compounds are expected to be used in monotherapy or combination to treat major indications

Approved Products

R&D Pipeline

Pipeline

Indication

NSCLC with METex14 skipping mutation

Stage

Preclinical
Phase I
Phase II
Phase III
NDA
Launched

NSCLC with METex14 skipping mutation(Confirmatory study)

Stage

Preclinical
Phase I
Phase II
Phase III
NDA

Immuno and chemo failure &MET overexpression NSCLC

Stage

Preclinical
Phase I
Phase II
Phase III
NDA

Indication

Advanced Gastric Cancer

Stage

Preclinical
Phase I
Phase II
Phase III
NDA

HER2-negative Breast Cancer

Stage

Preclinical
Phase I
Phase II
Phase III
NDA

Indication

Advanced ES and other advanced solid tumors

Stage

Preclinical
Phase I
Phase II
Phase III
NDA

Follicular Lymphoma

Stage

Preclinical
Phase I
Phase II
Phase III
NDA

PTCL

Stage

Preclinical
Phase I
Phase II
Phase III
NDA

Indication

Ovarian , Oviduct or Primary peritoneal clear cell carcinoma

Stage

Preclinical
Phase I
Phase II
Phase III
NDA

Breast Cancer(Combined endocrine therapy)

Stage

Preclinical
Phase I
Phase II
Phase III
NDA

Vascular malformations

Stage

Preclinical
Phase I
Phase II
Phase III
NDA

Advanced Solid Tumor

Stage

Preclinical
Phase I
Phase II
Phase III
NDA

Indication

Malignant hematoma, Solid Tumor

Stage

Preclinical
Phase I
Phase II
Phase III
NDA

Indication

Malignant hematoma, Solid Tumor

Stage

Preclinical
Phase I
Phase II
Phase III
NDA

Indication

Solid Tumor

Stage

Preclinical
Phase I
Phase II
Phase III
NDA

Indication

Solid Tumor

Stage

Preclinical
Phase I
Phase II
Phase III
NDA

Indication

Solid Tumor

Stage

Preclinical
Phase I
Phase II
Phase III
NDA

Indication

Solid Tumor

Stage

Preclinical
Phase I
Phase II
Phase III
NDA

Indication

Diabetic Foot Ulcer

Stage

Preclinical
Phase I
Phase II
Phase III
NDA

| Legal statement | Disclaimers | Contact |

Follow Us

©2020 Haihe Biopharma Co., Ltd.
All Rights Reserved 沪ICP备27408324号-1

Z6·尊龙凯时